Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

Share Price is delayed by 15 minutes
Get Live Data
9.00    0.00 (0.00%)
Bid:
7.00
Ask:
11.00
Spread: 4.00 (57.143%)
Market Cap: £2.98m
HYG Live PriceLast checked at - London Stock Exchange

Intraday Seneca Growth Share Chart

Updated NAV & Ordinary Share Class Dividend

15 Oct 2025 16:26

RNS Number : 5441D
Seneca Growth Capital VCT PLC
15 October 2025
 

Updated Net Asset Values and Ordinary Share Class Dividend Declaration

Seneca Growth Capital VCT Plc 

15 October 2025

 

Seneca Growth Capital VCT Plc

Unaudited Net Asset Value ("NAV") Update as at 30 September 2025

The Directors of Seneca Growth Capital VCT Plc (the "Company") and the Investment Manager of the Company, Seneca Partners Limited ("Seneca"), have reviewed the valuation of the Company's investment portfolios for the quarter ending 30 September 2025 and announce an updated NAV for each of the Company's Ordinary and B share classes as at 30 September 2025.

For the purposes of calculating the NAV per share for both share classes, quoted investments are valued in line with closing bid prices as at 30 September 2025 and unquoted investments are carried at fair value.

B share NAV as at 30 September 2025

As at 30 September 2025, the unaudited B share NAV was 47.7p per share, a 2% decrease from the previously published unaudited NAV as at 30 June 2025 of 48.7p.

The B share NAV Total Return was 67.2p compared to 68.2p as at 30 June 2025.

The 1.0p decrease in NAV per B share in the quarter is principally due to movements in the share prices of the B share pool's AIM/AQSE quoted investee companies during the quarter.

Ordinary share NAV as at 30 September 2025

As at 30 September 2025, the unaudited Ordinary share NAV was 13.1p per share, a 16% increase from the previously published unaudited NAV as at 30 June 2025 of 11.3p.

The Ordinary share NAV Total Return was 89.4p compared to 87.6p as at 30 June 2025.

The 1.8p increase in NAV per Ordinary share is principally due to the increase in the share price of AIM quoted Arecor Therapeutics Plc ("Arecor") and Scancell Holdings Plc ("Scancell").

Scancell was the largest holding in the Ordinary share portfolio, representing 92% of the Ordinary share NAV as at 30 June 2025. As a result, the Ordinary share NAV moved largely in line with the movement in the Scancell share price during the quarter. The Company was presented with an opportunity to de-risk the concentration of the holding for Ordinary shareholders and was able to achieve a profitable exit of c.47% of the Ordinary share pool's holding as at 30 June 2025. Seneca was able to realise £435k in proceeds from the disposal, which generated a profit of £172k, resulting in an average weighted return of 1.7x on original investment cost. This disposal has enabled the Company to declare a second interim capital dividend of 5.0p per Ordinary share.

The Ordinary share pool's unquoted investments have all previously been written down to £nil carrying value. The valuations of the Ordinary share pool's unquoted investments remain unchanged as at the quarter end.

Second Interim Capital Dividend on Ordinary Shares

The Directors of the Company are pleased to declare an interim capital dividend of 5.0 pence per Ordinary Share for the year to 31 December 2025, to be paid on 7 November 2025.

The ex-dividend date is 23 October 2025.

The record date for the dividend is 24 October 2025.

The dividend payment date is 7 November 2025.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.

For further information, please contact:

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Siobhan Pycroft, Seneca Partners Limited at Siobhan.Pycroft@senecapartners.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVPKPBBPBDDBKD
Date   Source Headline
19th Mar 20085:02 pmRNSAnnual Report and Accounts
14th Jan 20085:22 pmRNSUpdate letter to Shareholders
3rd Jul 20063:56 pmRNSCompany Secretary Change
10th May 20062:49 pmRNSPurchase of Own Securities
26th Apr 20062:50 pmRNSChange of Name
25th Apr 20065:02 pmRNSDirector's Shareholding
20th Apr 20067:01 amRNSBVCT Update
20th Apr 20067:00 amRNSResult of AGM
10th Apr 20063:23 pmRNSDirector/PDMR Shareholding
3rd Apr 20064:28 pmRNSDirector's Shareholding
29th Mar 20061:09 pmRNSAnnual Information Update
24th Mar 20064:19 pmRNSFinal Results
9th Mar 20067:00 amRNSInvestment Process & Strategy
11th Nov 20054:33 pmRNSDirectorate Change
4th Nov 20054:04 pmRNSResult of AGM
3rd Oct 200511:19 amRNSNotice of AGM
27th Sep 20057:00 amRNSInterim Results
1st Sep 20058:31 amRNSBoard Changes
16th Aug 20055:51 pmRNSVCT Status
16th Aug 20059:09 amRNSVCT Status
2nd Aug 200510:56 amRNSBoard Change
12th Jul 20055:04 pmRNSBoard Changes
29th Apr 200510:22 amRNSFinal Results
14th Feb 20054:02 pmRNSIssue of Equity
9th Feb 20052:20 pmRNSCancellation of Listing
8th Feb 200511:27 amRNSCancellation of Listing
28th Jan 20052:55 pmRNSIssue of Equity
14th Jan 20053:40 pmRNSHolding(s) in Company
5th Jan 20054:32 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.